The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Secukinumab Promising for Sustained Improvements in Palmoplantar & Nail Psoriasis

Secukinumab Promising for Sustained Improvements in Palmoplantar & Nail Psoriasis

February 28, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Palmoplantar and nail psoriasis significantly affect a patient’s quality of life. This negative impact can lead to reduced mobility, functional impairment and physical discomfort. In November 2017, data presented at the 8th International Congress of Psoriasis from Gene to Clinic in London showed that secukinumab treatment sustains improvements in nail and palmoplantar psoriasis for more than two years.1

You Might Also Like
  • One-Year Data Shows Apremilast Effective in Severe Scalp, Nail Psoriasis
  • Psoriatic Arthritis Patients Show Long-Term, Sustained Improvement with Secukinumab
  • Tofacitinib Treatment May Improve Nail Psoriasis
Also By This Author
  • FDA Update: FX006 Promising for Knee OA; Pioglitazone Linked to Bladder Cancer Risk; & HIV Drug Gets New Labeling

GESTURE was a randomized, placebo-controlled, clinical trial investigating the safety and efficacy of 150 and 300 mg doses of subcutaneous secukinumab in patients (n=205) with moderate to severe palmoplantar psoriasis. It is the largest and longest duration study of secukinumab evaluating this patient population. Secukinumab’s effect on sole skin and palm clearance was determined using the Palmoplantar Investigator’s Global Assessment (ppIGA) and Palmoplantar Psoriasis Area and Severity Index (ppPASI). Positive effects on quality of life were assessed via the Dermatology Life Quality Index (DLQI) and palmoplantar Quality of Life Instrument (ppQLI) scores.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study results showed that 59% of 300 mg secukinumab-treated patients and 53% of 150 mg secukinumab-treated patients obtained clear or almost clear palms and soles after two and a half years, as measured by ppIGA. Consistent benefits were seen in changes in the ppPASI score. The safety of secukinumab did not differ from other secukinumab clinical trials.

A second clinical trial, TRANSFIGURE, was a double-blind, randomized, placebo-controlled Phase 3b study investigating the long-term safety and efficacy of 150 and 300 mg doses of secukinumab in patients (n=198) with moderate to severe nail psoriasis. This study evaluated the superiority of these dosing regimens compared with placebo. Clinical effectiveness was evaluated at two and a half years using the Nail Psoriasis Severity Index (NAPSI) and Psoriasis Area and Severity Index (PASI). Quality of life effect was evaluated with the Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) and EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the study, a substantial NAPSI improvement from baseline of -73% for 300 mg secukinumab-treated patients and -63% for 150 mg secukinumab-treated patients was attained and sustained for up to two-and-a-half years. Improved NAPPA and EQ-5D scores highlighted the benefits to patient quality of life. Patients reported decreased discomfort and pain.

These studies are the first to confirm a biologic as both a safe and effective long-term treatment for palmoplantar and nail psoriasis.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: nail psoriasis, nails, palmoplantar psoriasis, Psoriasis, secukinumab

You Might Also Like:
  • One-Year Data Shows Apremilast Effective in Severe Scalp, Nail Psoriasis
  • Psoriatic Arthritis Patients Show Long-Term, Sustained Improvement with Secukinumab
  • Tofacitinib Treatment May Improve Nail Psoriasis
  • Secukinumab Meets 5-Year Benchmark for Psoriasis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)